A5100421032- Cancer-related molecular mechanisms research
- Lung Cancer Treatments and Mutations
- RNA modifications and cancer
- Circular RNAs in diseases
- Lung Cancer Research Studies
- MicroRNA in disease regulation
- Colorectal Cancer Treatments and Studies
- Lung Cancer Diagnosis and Treatment
- Cancer Immunotherapy and Biomarkers
- Cancer therapeutics and mechanisms
- Oral and Maxillofacial Pathology
- Cancer Genomics and Diagnostics
- Gastric Cancer Management and Outcomes
- Salivary Gland Tumors Diagnosis and Treatment
- Oral Health Pathology and Treatment
- Peroxisome Proliferator-Activated Receptors
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Neuroblastoma Research and Treatments
- Lipid metabolism and disorders
- Cancer-related gene regulation
- Mycobacterium research and diagnosis
- Genomics and Phylogenetic Studies
- Breast Cancer Treatment Studies
- Breast Implant and Reconstruction
- Pancreatic and Hepatic Oncology Research
Sichuan Cancer Hospital
2014-2024
University of Electronic Science and Technology of China
2020-2024
Second Affiliated Hospital of Nanjing Medical University
2018-2024
Xijing Hospital
2022
Soochow University
2020
First Affiliated Hospital of Soochow University
2020
Suzhou Research Institute
2020
Second Hospital of Shandong University
2018-2020
Shandong University
2019-2020
Jinan Central Hospital
2020
IntroductionSintilimab, an anti–programmed death 1 antibody, plus pemetrexed and platinum had revealed promising efficacy for nonsquamous NSCLC in a phase 1b study. We conducted randomized, double-blind, 3 study to compare the safety of sintilimab with placebo, both combination such chemotherapy (ClinicalTrials.gov: NCT03607539).MethodsA total 397 patients previously untreated, locally advanced or metastatic without sensitizing EGFR anaplastic lymphoma kinase genomic aberration were...
Aumolertinib (formerly almonertinib; HS-10296) is a novel third-generation epidermal growth factor receptor tyrosine kinase inhibitor approved in China. This double-blind phase III trial evaluated the efficacy and safety of aumolertinib compared with gefitinib as first-line treatment for locally advanced or metastatic EGFR-mutated non-small-cell lung cancer (NSCLC; ClinicalTrials.gov identifier: NCT03849768).Patients at 53 sites China were randomly assigned 1:1 to receive either (110 mg)...
Lung cancer is the first leading cause of deaths worldwide. Non‐small cell lung (NSCLC) most common type cancer. Increasing evidence shows that long noncoding RNA (lncRNA) are capable modulating tumor initiation, proliferation and metastasis. In present study, we aimed to evaluate whether circulating lncRNA could be used as biomarkers for diagnosis prognosis NSCLC. Expression profiles 14 selected from other studies were validated in 20 pairs tissues by quantitative real‐time PCR,...
IntroductionSintilimab plus chemotherapy significantly prolonged progression-free survival (PFS) compared with alone in nonsquamous NSCLC the ORIENT-11 study. Updated overall (OS) and PFS data corresponding biomarker analyses are reported here.MethodsIn this study, a total of 397 patients previously untreated, locally advanced or metastatic were assigned to sintilimab combination treatment (combo) group placebo group. The stratified by programmed death-ligand 1 (PD-L1) expression levels....
Abstract Some types of long noncoding RNAs (lncRNAs) are aberrantly expressed in human diseases, including cancer. However, the overall biological roles and clinical significances most lncRNAs colorectal cancer (CRC) not fully understood. First, The Cancer Genome Atlas (TCGA) was analyzed to identify differentially between CRC tissues noncancerous tissues. We identified that LINC02418 highly cell lines. Next, we evaluated effect on tumorigenesis its regulatory functions absorbing microRNA...
Abstract Cell‐free long non‐coding RNAs (lncRNAs) are stably present in urine and can serve as non‐invasive biomarkers for cancer. We aimed to identify signatures of lncRNAs diagnosis prognosis bladder cancer (BC). Screening by microarray analysis was performed using samples 10 BC patients controls. Expressions candidate were evaluated the training validation set including 230 controls quantitative reverse transcription polymerase chain reaction (qRT‐PCR). A two‐lncRNA panel (uc004cox.4...
IntroductionLorlatinib was found to have activity in ALK-positive NSCLC a global phase 1 and 2 study. We report an ongoing study Chinese patients with advanced or metastatic NSCLC.MethodsOpen-label, dual-cohort (NCT03909971); had progressive disease after ALK tyrosine kinase inhibitor treatment (cohort 1: previous crizotinib; cohort 2: one other than crizotinib [±prior crizotinib]), more equal unirradiated extracranial target lesion, Eastern Cooperative Oncology Group performance status of 0...
Abstract WX-0593 (Iruplinalkib) is a novel, highly selective oral ALK and ROS1 tyrosine kinase inhibitor (TKI). In this study, the safety, antitumor activity, pharmacokinetics of were evaluated in advanced non-small cell lung cancer (NSCLC) patients with or rearrangement. dose-escalation phase dose-expansion phase, treated until disease progression, unacceptable toxicity, subject withdrawal. primary endpoints maximum tolerated dose (MTD), dose-limiting toxicity (DLT), safety assessed by...
Colorectal cancer (CRC) is the third most common malignancy in world, and long noncoding RNA (lncRNA) plays a critical role carcinogenesis. Here, we report novel lncRNA, MAPKAPK5-AS1, that acts as oncogene CRC. In addition, attempted to explore functions of MAPKAPK5-AS1 on tumor progression vitro vivo. Quantitative RT-PCR was used examine expression CRC tissues cells. Expression significantly upregulated 50 tissues, increased found be associated with greater size advanced pathological stage...
9013 Background: Au is a novel, irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) with favorable pharmacologic properties that selectively inhibits both EGFR sensitizing and resistance mutations. has been approved in China for treatment of patients (pts) mutant NSCLC T790M upon progression disease on previous TKIs (Proc. AACR 2020, Abstract CT190). This Phase III trial assessed the efficacy safety versus G as initial advanced EGFRm. Methods: Pts previously...
Telmisartan, a member of the angiotensin II type 1 receptor blockers, is usually used for cardiovascular diseases. Recent studies have showed that telmisartan has property PPARγ activation. Meanwhile, essential tumor proliferation, invasion and metastasis. In this work we explore whether could exert anti-tumor effects through activation in A549 cells. MTT trypan blue exclusion assays were included to determine survival rates cell viabilities. RT-PCR western blotting analyze expression...
Abstract This single-arm, multi-center clinical trial aimed to evaluate the safety, tolerability, DLT, recommended dose (RD), preliminary efficacy, and pharmacokinetics (PK) characteristics of lurbinectedin, a selective inhibitor oncogenic transcription, in Chinese patients with advanced solid tumors, including relapsed SCLC. Patients tumors were recruited dose-escalation stage received lurbinectedin 3 + design (two cohorts: 2.5 mg/m 2 3.2 , IV, q3wk). The RD was expanded following...
BACKGROUND:Radio-resistance is an important barrier in nasopharyngeal carcinoma treatment. MicroRNAs are gene expression core regulators various biological procedures containing cancer radio-resistance. Nevertheless, the clinical association between and miR-193a-3p/SRSF2 remains unclear. MATERIAL AND METHODS:We examined miR-193a-3p level radio-sensitive CNE-2 radio-resistant CNE-1 NPC cell lines, and, based on a literature review, predicted SRSF2 to be target of miR-193a-3p. We explored at...
Accumulating literatures have indicated that long non-coding RNAs (lncRNAs) are crucial molecules in tumor progression various human cancers, including colorectal cancer (CRC). However, the clinical significance and regulatory mechanism of a vast majority lncRNAs CRC remain to be determined. The current study aimed explore function molecular lncRNA AC010789.1 progression. found overexpressed tissues cells. High expression was associated with lymph node metastasis poor prognosis. Moreover,...
Abstract Lung cancer is the primary cause of death among patients in China, which nonsmall cell lung (NSCLC) makes up great majority. Hence, it imperative to identify biomarkers and mechanisms involved NSCLC oncogenesis. Our present research found that KIAA1199 expression was significantly increased closely related proliferation, motility, poor prognosis. We demonstrated knockdown reduced growth motility vitro whereas overexpression had opposite effect. Inhibition suppressed tumor mouse...
Abstract Lung cancer is the dominating cause of cancer‐induced death and can be classified into small cell lung non–small (NSCLC). adenocarcinoma (LUAD) most common histological subtype NSCLC its pathology remains unclear. Mounting reports have revealed that lncRNAs could regulate cellular activities in cancers. Yet role ZFPM2 antisense RNA 1 (ZFPM2‐AS1) LUAD has not been elucidated. Using GEPIA online dataset, we identified amplification ZFPM2‐AS1 tissues. Through quantitative real‐time...
9096 Background: We previously reported (Lu, ASCO 2021, abstract # 9013) that treatment with aumolertinib (Au), a 3 rd generation EGFR TKI, led to robust improvement in progression free survival (PFS) (median PFS 19.3 9.9 months, HR = 0.46, p < 0.0001) when compared gefitinib (G) predictable and encouraging safety profile. This benefit was maintained across all prespecified stratification factors including the subset of ̃ 27% patients (pts) CNS metastases (HR 0.38). Here we undertook this...
Glioblastoma (GBM) is a highly invasive neurological malignancy with poor prognosis. LncRNA-GAS5 (growth arrest-specific transcript 5) tumor suppressor involved in multiple cancers. In this study, we explored the clinical significance, biological function, and underlying mechanisms of GAS5 GBM. We showed that lncRNA-GAS5 expression decreased high-grade glioma tissues cells, which might be associated overexpression lowered cell viability, suppressed GBM migration invasion, impaired stemness...